| UHS |
Report |
Adj. Operating EPS (Q2 2026) |
BEAT |
pred ~$6.30 vs. cons $5.96 |
MEDIUM |
| UHS |
Report |
Behavioral SS Adj. Patient Day Growth (Q2 2026) |
BEAT |
pred ~+2.0% vs. cons +1.66% |
MEDIUM |
| UHS |
Report |
Net Revenues (Q2 2026) |
BEAT |
pred ~$4.65B vs. cons $4.587B |
MEDIUM |
| UHS |
Guide |
Adj. Operating EPS (FY2026) |
BETTER |
guide ~$24.25 midpoint vs. cons $23.52 |
MEDIUM |
| UHS |
Guide |
Net Revenues (FY2026) |
BETTER |
guide ~$18.80B midpoint vs. cons $18.55B |
MEDIUM |
| UHS |
Guide |
Behavioral SS Vol. Growth (FY2026) |
UNCHANGED |
reaffirm 2%-3% range vs. cons ~2.0% |
HIGH |
| UHS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| UHS |
Return |
5-day cumulative residual |
+2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side H2 estimate revisions catch up to FY raise; partially offset by pre-earnings run being given back |
MEDIUM |